'Gut-on-chip' can predict immunotherapy outcomes for melanoma patients
A team of researchers has developed a "gut-on-chip" (a miniature model of the human intestine on a chip-sized device) capable ...
FiercePharma17h
Bristol Myers Squibb comes up short in bid to expand Opdualag in melanoma
Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...
ENDPOINTS NEWS14h
Bris­tol My­ers’ Op­du­alag stum­bles in late-stage re­sect­ed melanoma tri­al
Bristol Myers Squibb's Opdualag (relatlimab/Opdivo) fails Phase 3 melanoma trial, adding to mixed results for LAG-3/PD-1 ...
BioSpace15h
BMS’ Phase III Opdualag Melanoma Fail Could Limit Market Opportunity: Analysts
The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.